Research paper
Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
Study answer
What this study found
NEC was feasible and well tolerated, but it did not show clear efficacy for aromatase inhibitor-induced arthropathy in this small pilot study. FACT-ES change at 3 months favored NEC (+7.1, SD 15.6) over placebo (-7.4, SD 15.0), with between-arm p=0.039, but other patient-reported outcomes and grip strength did not show significant between-arm differences. Within-arm FACT-ES changes were not significant (NEC p=0.08; placebo p=0.14), and grip strength results were mixed (right hand p=0.44, left hand p=0.07; combined increase >2 kg in 7 NEC readings vs 4 placebo readings, p=0.05). Plasma…
- Study & population
- This was a multisite randomized, placebo-controlled, double-blind pilot trial.
- Intervention
- Nanoemulsion curcumin (NEC) was given orally as capsules at a total dose of 200 mg/day of curcumin, dosed as 1 capsule twice daily for 3 months.
- Key limitation
- Small sample size and pilot design limit inference, and the study was not powered to assess efficacy.
View source
Open PDFOriginal abstract
Aromatase inhibitor (AI) therapy reduces risk of recurrence and death for postmenopausal women with breast cancer (BC); however, AI-induced arthralgia (AIIA) can lead to discontinuation of treatment. Curcumin, a bioactive polyphenolic substance, may …